Origami Therapeutics is developing medicines that target and degrade disease-related proteins as a means of treating disease. They're a preclinical biopharmaceutical company determined to find innovative treatments for neurological disorders, starting with Huntington's disease. Their new protein degraders digest and eliminate disease-causing proteins by utilizing the body's natural protein disposal system. Neurodegenerative disorders such as Alzheimer's, Parkinson's, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia are the target of its core programs.